Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/15/25
End: 08/31/34
Due: 08/31/35
Phase: N/A
Priority: Normal
Start: 08/14/20
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 09/17/20
End: 06/30/25
Due: 06/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | NCT06493552 | Vasgene Therapeutics, Inc | user2@example.com | None | 2025-03-15 | 2034-08-31 | 2035-08-31 | - | - | 2025-07-14 |
| A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | NCT04486781 | Vasgene Therapeutics, Inc | user2@example.com | None | 2020-08-14 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| A Study of sEphB4-HSA in Kaposi Sarcoma | NCT03993106 | Vasgene Therapeutics, Inc | user2@example.com | None | 2020-09-17 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |